Picture of Celyad Oncology SA logo

CYAD — Celyad Oncology SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Brief: Celyad Ended Q3 With 55.9 Million Euros In Cash, Cash Equivalents And Short-Term investments

Nov 21 (Reuters) - CELYAD SA  CYAD.BR :
    * ENDED Q3 WITH EUR 55.9 MILLION IN CASH, CASH EQUIVALENTS
AND
SHORT-TERM
INVESTMENTS
    * CONFIRMS ITS PREVIOUS GUIDANCE THAT EXISTING CASH, CASH
EQUIVALENTS
AND SHORT-TERM INVESTMENTS SHOULD BE SUFFICIENT UNTIL MID-2020

Source text for Eikon:  ID:nGNXb4rPLx 
Further company coverage:  CYAD.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))

Recent news on Celyad Oncology SA

See all news